Rationale: Alpha-1 antitrypsin deficiency, caused primarily by homozygosity for the Z allele of the SERPINA1 gene, is a wellestablished genetic cause of chronic obstructive pulmonary disease (COPD). Whether the heterozygous PiMZ genotype for alpha-1 antitrypsin confers increased risk for COPD has been debated.
Severe alpha-1 antitrypsin (AAT) deficiency, a well-established genetic risk factor for chronic obstructive pulmonary disease (COPD), is relatively common in populations of European ancestry, occurring in about 1 in 3,000 individuals (1) . Most commonly, patients with severe AAT deficiency inherit two copies of the protease inhibitor (SERPINA1) Z allele; they have a PiZZ genotype and a PiZ protein phenotype. PiZZ individuals have approximately 15% of the normal plasma AAT levels because the Z protein polymerizes in the endoplasmic reticulum of hepatocytes (2) . In addition to the rare Z allele, a large number of additional genetic variants in the SERPINA1 gene have been described. The most common alleles are the family of M alleles, which confer normal serum AAT levels, although the S allele, which confers mildly reduced AAT levels, is also relatively common. Individuals who inherit one Z allele and one of the heterogeneous group of very rare Pi-null alleles (PiZ-null genotype and PiZ protein phenotype) are also at substantially increased risk for COPD. Individuals with the PiZ protein phenotype are at especially increased risk for developing COPD if they smoke (3, 4) . Though African Americans, admixed with varying proportions of European and African ancestry, are infrequently affected by severe AAT deficiency, the frequency is not negligible (5) .
Whether there is increased risk for the development of COPD in individuals who are heterozygous for the SERPINA1 PiMZ genotype is debatable. The literature to date is inconclusive, with divergent results (6) (7) (8) (9) (10) . A metaanalysis demonstrated increased risk for COPD among PiMZ individuals in casecontrol studies but no reduction in FEV 1 in PiMZ individuals in population-based studies (11) . We analyzed subjects with the PiMZ genotype from two racial groups in the Genetic Epidemiology of COPD (COPDGene) Study. We hypothesized that the PiMZ genotype would be associated with COPD affection status, lung function level, and percent emphysema based on volumetric chest computed tomography (CT) in both racial groups.
Methods

Study Recruitment
The COPDGene Study is a multicenter, longitudinal study of 10,192 non-Hispanic white (NHW) and non-Hispanic African American (NHAA) smokers with and without COPD. The COPDGene Study was designed to characterize subjects with COPD clinically, physiologically, genetically, and longitudinally. The present analysis was restricted to smoking control subjects and those classified as Global Initiative for Chronic Obstructive Lung Disease (GOLD) spirometric grades 1-4 from both racial groups (12) . Study subjects with preserved ratio impaired spirometry (n = 1,257) were excluded (13) .
Study participants were between the ages of 45 and 80 years at enrollment and had a smoking history of at least 10 pack-years. Spirometry was performed before and after bronchodilator administration with an EasyOne spirometer (ndd Medical, Andover, MA) using the Third National Health and Nutrition Examination Survey reference prediction equations (14) . We report only post-bronchodilator spirometric values. Slicer quantitative image analysis software (www.slicer.org) was used to determine percent emphysema and percent gas trapping from multidetector volumetric CT scans of the thorax. Total lung emphysema was measured using density mask analysis at 2950 Hounsfield units on inspiratory CT (15) (16, 17) .
Genotyping
Genotyping for the SERPINA1 Z (rs28929474) and S (rs17580) alleles was performed with 59 to 39 exonuclease assays implemented using the TaqMan assay (Applied Biosystems, Foster City, CA) with at least 99% genotype passing rates. The assays were compared with known PiZZ, PiMZ, and Coriell Institute for Medical Research (Camden, NJ) control samples. All PiZZ and PiMZ calls were confirmed by repeat genotyping. All non-S and non-Z subjects were considered to be PiMM, although we recognize that some rare deficiency and nondeficiency alleles were not appropriately classified using this approach.
Pi Protein Phenotyping
As additional confirmation of the SERPINA1 genotyping results and to assess for rare genotypes (e.g., Z-null), isoelectric focusing was performed on plasma samples from subjects with the PiZZ, PiSZ, and PiMZ genotypes (18, 19) . Discordance between the genotyping and protein phenotyping was resolved by medication review for AAT augmentation therapy as well as by repeat genotyping and protein phenotyping. Two subjects with irreconcilable discrepancies were deleted from the analysis. 
Results
AAT genotyping for the Pi*Z and Pi*S alleles was performed for all subjects enrolled in the COPDGene Study. Genetic samples were excluded from analysis for sample quality issues or subject ineligibility. Samples with discrepancies due to race or sex mismatch (mixed race, n = 7), mislabeling or failed sample (n = 14), insufficient samples (n = 41), or duplications based on genome-wide association analysis were excluded. Subjects with significant bronchiectasis or interstitial lung disease detected on volumetric CT scans (n = 64) were also excluded. Two PiMZ subjects, one each with bronchiectasis or interstitial lung disease, were excluded. One subject with PiZZ AAT deficiency had bronchiectasis.
To best discriminate the association of the PiMZ genotype on COPD and COPDrelated traits, this study was limited to 8,827 individuals spirometrically classified as smoking control subjects (n = 4,374) and GOLD spirometric grades 1-4 (n = 4,453) (12) . Chest CT scans were available for 8,571 (97%) of these subjects. Of the 8,827 subjects with genotypes passing stringent quality controls, 8,271 had the PiMM or PiMZ genotype. Chest CT scans were available for 8,035 (97%) subjects identified as PiMM or PiMZ.
Of 8,271 subjects with PiMZ and PiMM genotypes, 3% were PiMZ by genotype (Table 1) . Although known severe AAT deficiency was an exclusion criterion for the COPDGene Study, we identified seven PiZZ subjects and one PiZ-null subject. Medication review revealed that six of these subjects were receiving AAT augmentation therapy, indicating that they had previously been diagnosed with severe AAT deficiency. PiMZ and PiMM subjects were similar with regard to age at smoking initiation, pack-years of smoking, and smoking duration (P . 0.05, respectively). Despite similar smoking intensities, PiMZ subjects were less likely to be current cigarette smokers (P , 0.0001), were older (age, 63 yr [SD, 9] vs. 60 yr [SD, 9] ; P , 0.0001), and exhibited lower lung function. FEV 1 percent predicted was 10% lower in PiMZ subjects, on average (68% [SD, 28] vs. 78% [SD, 27] ; P , 0.0001). Globally assessed by volumetric CT scanning of the thorax, PiMZ subjects had 4% more radiographic emphysema, on average (P , 0.0001), and 4% more emphysema in the upper third and lower third of the lung zones (P , 0.0001), respectively. PiMZ subjects exhibited 7% more gas trapping (P , 0.0001) concurrent with an increased estimated FRC (P = 0.0006). The distribution of SERPINA1 genotypes in all subjects is displayed in Table 2 . The COPDGene Investigators enrolled larger numbers of African American smoking control subjects than subjects with COPD; therefore, some of these observed differences in lung function and CT parameters could be related to lower PiMZ prevalence in NHAA subjects, who were also, on average, healthier than the NHW subjects. Thereafter, the remaining analyses were performed after stratification by racial group.
Characteristics of NHW Subjects with PiMZ versus PiMM Genotype
Of 5,518 NHW subjects in this analysis, 4% were PiMZ by genotype. Characteristics of NHW versus NHAA PiMZ subjects are displayed in Table 3 . Compared with PiMM subjects, PiMZ subjects did not differ in age of onset of smoking, pack-years of smoking, duration of smoking, BMI, or BODE Index (body mass index, airflow obstruction, dyspnea, and exercise capacity) (P . 0.05, respectively) (20) . However, NHW PiMZ subjects included 14% fewer current smokers than NHW PiMM subjects (P , 0.0001). NHW PiMZ subjects also had significantly lower lung function, FEV 1 percent predicted (68 6 28 vs. 75 6 27; P = 0.0005) and FEV 1 /FVC ratio (0.59 6 0.18 vs. 0.63 6 0.17; P = 0.0008). In Definition of abbreviations: NHAA = nonHispanic African American; NHW = non-Hispanic white. Note: Although only the S and Z alleles were detected by genotyping, other rare alleles (e.g., F, I, and null) were identified in the subset of individuals who underwent protein phenotyping. One of the seven PiZZ subjects was subsequently removed from the COPDGene data set based on the presence of significant bronchiectasis.
ORIGINAL RESEARCH generalized linear models controlling for age, sex, and pack-years of smoking, analyzed with (P = 0.001) and without current smoking (P = 0.0008), PiMZ genotype in NHW subjects was associated with a 5% mean reduction in FEV 1 percent predicted ( Table 4 ). The proportion of subjects with severe and very severe COPD, spirometrically classified as GOLD grade 3 or GOLD grade 4, was higher in PiMZ subjects than in PiMM subjects (18 vs. 15% and 12 vs. 8%, respectively; P = 0.04 for difference in distribution across GOLD grades). (Figure 1) . A higher proportion of NHW PiMZ subjects met the GOLD spirometric criteria for moderate or greater COPD (60 vs. 52%; P = 0.02). PiMZ subjects had increased odds for COPD affection status in univariate analysis (odds ratio, 1.4; 95% confidence interval [CI], 1.01-1.9; P = 0.02). In a model controlling for age, sex, packyears of smoking, and BMI, NHW with the PiMZ genotype had nearly 40% greater odds for COPD (1.4; 95% CI, 1.03-1.9; P = 0.03). Similar results were obtained in a model including current smoking ( Table 4) .
As shown in Figure 2 , NHW PiMZ subjects exhibited absolute increases in radiographic emphysema (globally, 11% [SD, 13] ; P , 0.001). These subjects also exhibited more expiratory gas trapping (30% [SD, 22] vs. 26% [SD, 21] ; P = 0.0007) (Figure 2 ). In generalized linear models with log-transformed, CT-derived imaging phenotypes, controlling for sex, pack-years of smoking, BMI, current smoking, and scanner type, PiMZ genotype was significantly associated with CT emphysema in NHW subjects (0.30 [SE, 0.09]; P = 0.001).
In generalized linear models with identical covariates, PiMZ subjects had significantly more radiographic emphysema when the analysis was confined to the upper one-third of the lung fields (0.32 [SE, 0.12]; P = 0.006). PiMZ genotype was similarly associated with significantly more emphysema in the lower one-third of lung fields in the same model (0.31 [SE, 0.09]; P = 0.0007). Our data suggest that, compared with PiMM subjects, NHW individuals with the PiMZ genotype exhibited more gas trapping in multivariable models controlling for the same covariates (0.13 [SE, 0.06]; P = 0.052), but this was of borderline statistical significance with current smoking adjustment.
Characteristics of NHAA Subjects with PiMZ versus PiMM
Of 2,753 NHAA current or former smokers, spirometrically classified as exhibiting normal lung function through GOLD grade 4, the PiMZ genotype occurred in 0.8% (n = 22). NHAA PiMZ subjects did not differ in age, pack-years of smoking, duration of smoking, or BMI (P . 0.05, respectively) from NHAA PiMM subjects. PiMZ subjects were less likely to be current smokers (80 vs. 41%; P , 0.0001). BODE Index was higher, on average (2.8 vs. 1.4; P = 0.02), in NHAA PiMZ subjects than in NHAA subjects with the PiMM genotype.
In univariate analysis, FEV 1 percent predicted was reduced by nearly 20% in NHAA PiMZ subjects (65% [SD, 33] In generalized linear models with NHAA subjects, controlling for age, sex, and pack-years of smoking, with or without current smoking, we observed that PiMZ genotype was independently associated with FEV 1 percent predicted (P = 0.009 and P = 0.0002, respectively) and FEV 1 /FVC (P = 0.02 and P = 0.0008, respectively) ( Table 5 ). In generalized linear models with NHAA subjects, controlling for age, sex, pack-years of smoking, BMI, and scanner type (and without current smoking as a covariate), we observed that PiMZ genotype was associated with radiographic emphysema; however, this association was not significant after controlling for current smoking. In logistic regression analysis for COPD affection status in NHAA subjects, we found that PiMZ genotype was associated with COPD in a model controlling for age, sex, pack-years of smoking and BMI (odds ratio, 2.9; 95% CI, 1.1-7.4; P = 0.03), but this effect was lost when current smoking was added as an additional covariate. The regression models for PiMZ genotype and lung function showed significant associations with PiMZ genotype, regardless of whether current smoking was included as a covariate in the models (Table 5) .
Discussion
In our analysis of COPDGene Study subjects, we demonstrated associations of PiMZ genotype with COPD, lung function, and CT emphysema. Compared with PiMM subjects, NHW PiMZ current or former smokers had 1.4 times greater odds of having COPD. There were strong associations between PiMZ genotype, CT emphysema, and gas trapping in NHW. Adjustment for current smoking did not substantially change the associations between COPD affection status, spirometric phenotypes, or CT phenotypes and PiMZ in the NHW COPDGene subjects. However, the association of COPD with PiMZ was attenuated with current smoking adjustment in the NHAA COPDGene subjects. We suspect that this relates to the small number of African American PiMZ individuals in the COPDGene Study. Of interest, FEV 1 and FEV 1 /FVC continued to show associations with PiMZ among African Americans, even after current smoking adjustment. The association of PiMZ genotype with reduction in lung function is robust, with consistency and concordance in both racial groups. An additional strength of our findings is that several radiographic associations were unchanged after controlling for current smoking, because lung tissue density on CT scans may be increased by active smoking in a dosedependent fashion (21) . We also found lower rates of current smoking among PiMZ subjects, which likely relates to their higher rates of COPD.
PiMZ individuals have intermediate AAT levels compared with PiMM individuals, at approximately 60% of normal levels (22) . There has been uncertainty whether the PiMZ genotype is a risk factor for the development for COPD (8, 10) . Other studies are supportive of the association (9, 11, (23) (24) (25) (26) . Several recent larger studies have supported a significant COPD risk in PiMZ subjects (27) . In the International COPD Genetics Network and Genetics of Chronic Obstructive Lung Disease (GenKOLS) populations, Sørheim and colleagues demonstrated reduced FEV 1 /FVC in PiMZ subjects (24) . In a subset of subjects in the Swiss Cohort Study on Air Pollution and Lung and Heart Diseases in Adults (SAPALDIA), a Swiss population study of air pollution and heart or lung disease, PiMZ heterozygosity was associated with steeper declines in FEF 25-75% over time in subjects who were deemed to have chronically elevated lowgrade inflammation (28) . Molloy and colleagues recently performed a familybased study of PiMZ heterozygosity and risk for COPD in Irish families ascertained through PiMZ probands with COPD. They found that PiMZ was associated with an odds ratio of 5.18 (95% CI, 1.27-21.15; P = 0.02) that increased to 10.65 (95% CI, 2.17-52.29; P = 0.004) in ever smokers (29) . The conclusions drawn from this family-based study are concordant with our results, which is important because family-based studies have a reduced likelihood of false-positive results due to unrecognized population stratification (8, 26, 30, 31) .
Genome-wide association studies (GWASs) of COPD have identified multiple genomic regions associated with COPD susceptibility with genome-wide significance (32) (33) (34) (35) (36) . However, likely owing to the low frequency of the Z allele (approximately 1% in white populations), these COPD GWASs have not detected a genome-wide significant signal for the SERPINA1 locus. Of interest, in a collaborative GWAS of quantitative CT emphysema (including COPDGene), a more specific phenotype related to AAT deficiency, researchers did find a genomewide significant association located near the SERPINA1 locus, and the association evidence was substantially reduced with adjustment for the imputed Z-allele genotypes (17) . A collaborative exome chip study (including COPDGene), which included uncommon coding variants, did find nominal evidence for association of the SERPINA1 Z allele with COPD susceptibility (37) . The validated PiMZ genotypes in this study extend these previous observations and confirm that the PiMZ genotype is likely a significant risk factor for COPD susceptibility.
Though we provide substantial additional support for the association of PiMZ heterozygosity and COPD risk, we acknowledge potential limitations. Because the focus of the study is on the genetic determinants for COPD, ascertainment was based on smoking status. We did not evaluate risk for, and the results are therefore not generalizable to, nonsmokers. Additionally, our data do not provide an accurate assessment of the prevalence of severe AAT deficiency, because known subjects with AAT deficiency were not eligible for inclusion.
It is recommended that all individuals with COPD be tested for AAT deficiency, but targeted detection has not been widely embraced by practicing physicians (18) . These guidelines suggest that targeted detection in nontraditional populations (i.e., nonwhite) should be further ORIGINAL RESEARCH investigated (38) . Our data suggest that identification of PiMZ heterozygosity is important in African Americans, who often have not been considered for targeted detection. Our findings also support the use of AAT tests that provide genotype information (e.g., molecular genotyping or protein phenotyping) in testing symptomatic subjects, also optimizing the detection of PiMZ subjects (27) . The identification of PiMZ heterozygosity should lead to counseling against smoking 
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and other environmental exposures that may increase the risk for COPD. However, these results do not alter the recommendations regarding the inappropriateness of AAT augmentation therapy in PiMZ individuals (39) . Understanding the risks associated with heterozygous states has public health implications because those genotypes are substantially more prevalent than severe AAT deficiency. Our data substantiate the evolving paradigm that AAT PiMZ heterozygosity is a significant risk factor for COPD in smokers. n Author disclosures are available with the text of this article at www.atsjournals.org. ORIGINAL RESEARCH
